Focalpoint Partners invests in early stage biotech and deeptech companies with an emphasis on treating CNS and psychiatric disorders.
Investments include:
TippingPoint Biosciences
: epigenetic medicine for brain cancer, 2024
Stealth Biotech
: tackling rare neurological disorders, 2024
Aperture Therapeutics
: genetic medicine for neurodegeneration, 2024
Kerna Labs
: foundation models for better RNA therapeutics, 2024
NeuroBionics
: minimally invasive DBS leads, 2024
Pepper Bio
: leveraging phosphoproteomics to find drug targets, 2023
Tara Mind
: Ketamine therapy as an employee benefit, 2023
Superpower
: digital longevity clinic, 2023
Motif Neurotech
: minimally invasive TMS implant for depression, 2022
Psylo
: neuroplastogens for CNS disorders, 2022
Pangea Bio
: nature inspired drug discovery, 2022
Lykos Therapeutics
: MDMA assisted therapy for PTSD, 2022
Kadence Bio
: serotonin modulators for sexual dysfunction, 2022
Freedom Biosciences
: better Ketamine, 2022
Mindstate Design Labs
: next generation psychedelic experiences, 2021
Wavepaths
: music as medicine, 2021
Focalpoint is managed by
Brom Rector
and
Sam Tabone
and based in Los Angeles.
Contact:
hello at our domain
